Division of Paediatric Cardiology, University Children's Hospital, Zurich, Switzerland.
Int J Cardiol. 2010 Sep 3;143(3):373-7. doi: 10.1016/j.ijcard.2009.03.086. Epub 2009 Apr 14.
To report usability, safety, and efficacy of the self-centering Solysafe Septal Occluder for transcatheter closure of secundum type atrial septal defect (ASD) in paediatric patients.
Retrospective observational clinical study in two tertiary care centers for congenital heart diseases.
First 37 (median age 8.7 years, 68% female) consecutive patients with an ASD stretched diameter up to 22 mm in whom a Solysafe Septal Occluder was used to close a haemodynamically significant ASD.
Transcatheter closure of ASD was performed under general anaesthesia with trans-esophageal echo guidance. Stretched diameter of the ASD was assessed by balloon sizing.
Rate of success, complete closure rate, and complications (defined as vascular complications, device-related complications such as embolism, thrombus formation, device erosions, infections, and arrhythmia) during follow up.
37 procedures were performed, success rate was 87% (32 of 37 pts.). A missing retroaortic rim was the main reason for device failure. Complete ASD closure rate was 78% immediately in cath lab (25 of 32 pts.), 90% after four weeks (28 of 31 pts.), 94% after three months (29 of 31 pts.), and 100% after six months (20 of 20 pts.). Procedure-related complication was femoral vein thrombosis in one patient.
The Solysafe Septal Occluder is a feasible, safe, and clinically efficient new device for interventional closure of small to medium sized ASDs less than 23 mm stretched diameter in childhood. Limitations for the Solysafe device are ASDs with absent retroaortic rims and very small children with a body weight<10 kg.
报告经导管封堵小儿继发孔型房间隔缺损(ASD)使用自定心 Solysafe 隔瓣型封堵器的安全性、易用性和疗效。
在两家先天性心脏病三级护理中心进行回顾性观察性临床研究。
37 例(中位年龄 8.7 岁,68%为女性)连续 ASD 患者,ASD 伸展直径最大 22mm,使用 Solysafe 隔瓣型封堵器对其进行经导管封堵。
在全身麻醉下经食管超声心动图引导下进行 ASD 经导管封堵。通过球囊测量 ASD 的伸展直径。
成功率、完全封堵率和并发症(定义为血管并发症、器械相关并发症,如栓塞、血栓形成、器械侵蚀、感染和心律失常)。
共进行了 37 例手术,成功率为 87%(32/37 例)。器械失败的主要原因是无后主动脉瓣环。即刻在导管室 ASD 完全封堵率为 78%(32/32 例),4 周后为 90%(28/31 例),3 个月后为 94%(29/31 例),6 个月后为 100%(20/20 例)。1 例患者发生股静脉血栓形成。
Solysafe 隔瓣型封堵器是一种可行、安全且在临床上有效的新型装置,可用于介入封堵小儿 ASD,伸展直径<23mm,且<10kg 体重的极小患儿除外。该装置的局限性为无后主动脉瓣环的 ASD 和非常小的患儿。